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ABSTRACT 
Liver transplantation was the product of 5 interlocking themes. These 
began in 1958-59 with canine studies of then theoretical hepatotrophic molecules 
in portal venous blood (Theme I) and with the contemporaneous parallel 
development of liver and multivisceral transplant models (Theme II). Further 
Theme I investigations showed that insulin was the principal, although not the 
only, portal hepatotrophic factor. In addition to resolving long-standing 
controversies about the pathophysiology of portacaval shunt, the hepatotrophic 
studies blazed new trails in the regulation of liver size, function, and 
regeneration. They also targeted inborn metabolic errors (e.g. familial 
hyperlipoproteinemia) whose palliation by portal diversion presaged definitive 
correction with liver-replacement. Clinical use of the Theme II transplant models 
depended on multiple drug immunosuppression (Theme III, Immunology), guided 
by an empirical algorithm of pattern recognition and therapeutic response. 
Successful liver replacement was first accomplished in 1967 with azathioprine, 
prednisone, and ALG. With this regimen, the world's longest surviving liver 
recipient is now 40 years postoperative. Incremental improvements in survival 
outcome occurred (Theme IV) when azathioprine was replaced by cyclosporine 
(1979) which was replaced in turn by tacrolimus (1989). However, the biologic 
meaning of alloengraftment remained enigmatic until multilineage donor 
leukocyte microchimerism was discovered in 1992 in long surviving organ 
recipients. Seminal mechanisms were then identified (clonal exhaustion-deletion 
and immune ignorance) that linked organ engraftment and the acquired tolerance 
of bone marrow transplantation and eVentually clarified the relationship of 
transplantation immunology to the immunology of infections, neoplasms, and 
autoimmune disorders. With this insight, better strategies of immunosuppression 
have evolved. As liver and other kinds of organ transplantation became 
accepted as health care standards, the ethical, legal, equity, and the other 
humanism issues of Theme V have been resolved less conclusively than the 
medical-scientific problems of Themes I-IV. 
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The purpose of this contribution to the Master's Perspective Series is to 
describe in detail the provenance of liver replacement. In the absence until now 
of such an account, liver transplantation often has been characterized as a 
natural extension of renal transplantation. In reality, liver and kidney 
transplantation were co-developed with the liver as the flagship organ, or 
alternatively the engine, for much of the time. In the process, the rising tide of 
organ transplantation altered the practice of hepatology, nephrology, and other 
organ-defined medical specialties, enriched multiple areas of basic and clinical 
science, and had pervasive ripple effects in law, public policy, ethics, and 
religion. 
At first, liver transplantation was a fantasy. Transformation of the idea into 
a reality required the essentially de novo development between 1957 and 1962 
of 5 separate but interconnected themes: (I) metabolic interactions between 
intra-abdominal organs (hepatotrophic physiology), (II) the liver and multivisceral 
transplant models including donor organ procurement and preservation, (III) the 
immune system and its control without or with therapeutic immunosuppression, 
(IV) transplantation outcomes, and (V) humanism-associated issues (social, 
ethical, legal, public policy). 
The 5 themes can be used to categorize all of the liver transplant 
milestones of the last half century (1-71) as has been done by thematic color-
coding and by numbers in Table 1. To help connect this history with the present 
and future, John Fung was recruited as a collaborating author, fresh from his 5-
year tenure as Chief Editor of Hepatology's sister journal, Liver Transplantation. 
MY LlVERLESS EARLY LIFE 
I was born in 1926 in the small town of LeMars, Iowa, and remained there 
uneventfully until joining the United States Navy directly from high school in 1944 
(72). After the war's end, I remained "in training" fOr 14 consecutive years, 
beginning at Westminster College (Fulton, Missouri), and continuing in 
chronologie order at the university medical centers of Northwestern, UCLA, 
Johns Hopkins, Miami, and again Northwestern. Tangible results from this 
period included PhD and MD diplomas (Northwestern, 1952), board certificates in 
general and thoracic surgery, and a dozen publications of which the first 5 were 
in neuroscience. 
The Neuroscience Venture 
My research on the brain stem circuitry of cats (and eventually monkeys) 
was started at Northwestern at the age of 23 years under the neurophysiology 
pioneer, Horace W. Magoun and finished at UCLA after Magoun's recruitment 
there as one of the new school'S founding chairpersons. Each of the 5 resulting 
publications (73-77) generated 100 to 300 citations, and a figure from one (75) 
was immortalized as the logo of the UCLA Brain Institute. However, the Ph.D. 
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thesis from this research and completion of the Northwestern M.D. requirements 
marked the end of my neurophysiology career at the age of 26 years. 
The science environment that existed 60 years ago at both Northwestern 
and UCLA was described in my long letter of response in 1991 to a request by a 
UCLA Brain Institute archivist (see Supplementary Appendix #1). As described 
in that letter, Magoun's influence cut deeply. He had no interest in, and very little 
tolerance for, research that did not have a clear mega-purpose. In our project, 
the global objective was to delineate with electrophysiologic technology the 
neural pathways serving the most fundamental elements of brain function: sleep 
versus wakefulness, cognition, and memory. 
A Side Trip to Cardiac.Physiology 
The Supplementary Appendix #1 also contains a 1951 letter (discovered 4 
decades later) from Magoun to Alfred Blalock, Chairman of Surgery at the Johns 
Hopkins Hospital, that undoubtedly contributed to my acceptance for surgical 
training at that great institution (1952-56). After completing the first year in 
Baltimore, I put aside all clinical work for 18 months to develop a model of 
complete heart block in dogs, a complication being caused in patients by efforts 
to close atrial or ventricular septal defects. 
With the technology adapted from my neurophysiology experience, I 
showed that low voltage bipolar stimulation at any place on the ventricle was safe 
and efficient treatment for the bradycardia of heart block. The cardiac 
pacemaking was promptly instituted clinically at Hopkins and elsewhere. 
Although the articles describing the experimental work (78-80) also were 
frequently cited, my involvement in the subject of heart block now reached a 
dead end. 
However, the youthful excursions were not wasted. What survived from 
my exposure to Magoun, and was evident in the heart block research, was the 
view that all biologic functions were products of a hierarchy of interacting 
systems and subsystems over which there were controls at multiple levels (Le. 
regulatory brain equivalents). In this context, it was more important to learn how 
a given function was governed than to endlessly pursue details. The "big picture" 
approach (systems biology) WOUld, in fact, be applied to liver transplantation, the 
third subject to which I directed concentrated attention. 
THE SUCCESSION OF THEMES 
Anatomically-influenced physiologic interactions between organs (Theme I) 
While still at Johns Hopkins, I assisted Dr. Blalock perform a spienorenal 
shunt in a cirrhotic patient with insulin-dependent diabetes mellitus who then 
became insulin-free. The possibility that the portal diversion was responsible for 
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the metabolic change seemed consistent with a then current hypothesis that 
excessive degradation of endogenous insulin during its primary passage to the 
liver via the portal vein was the cause of some forms of diabetes (81). Testing 
elements of this hypothesis was not possible until after I moved to the new 
medical school of the University of Miami to complete my general surgery 
residency (1956-58). 
In Miami, I produced a colony of alloxan diabetic dogs, established the 
animals' steady state insulin needs, and modified the liver's blood supply with 
portacaval shunt (Eck's fistula) or other alterations of the portal venous system 
(82,83). The objective of surgically ameliorating diabetes evaporated when the 
portal diversion procedures increased instead of decreasing the insulin 
requirements (83). In addition, the hepatic atrophy and systemic morbidity 
caused by portacaval shunt in normal dogs (84,85) appeared to be exaggerated 
in our diabetic animals. 
Development of liver transplant models (Theme II) 
A connection of these studies to liver transplantation was made when C. 
Stuart Welch of Albany, New York, visited Miami in 1957 to give a lecture on the 
treatment of portal hypertension. During his talk, Welch made casual reference 
to a canine operation that he had reported in 1955 (1) and more extensively a 
year later (86). In these articles, the term "liver transplantation" was used for the 
first time in the scientific literature. The Welch operation consisted of 
revascularization of an auxiliary liver allograft in the recipient's right paravertebral 
gutter with provision of portal venous inflow from the inferior vena cava (Figure 
1 ). 
Recognizing that failure to provide the extra liver with a normal portal 
venous supply could handicap the allograft in the same way as the native livers 
were damaged in my non-transplant portal diversion models, I began the 
development of versatile transplant procedures to study the special qualities of 
splanchnic venous blood in dogs. One of the models was a method of total 
recipient hepatectomy, the unique feature of which was preservation of the 
retrohepatic inferior vena cava (2) as in the first stage of today's piggy-back 
human liver transplantation. For liver allograft implantation, it was technically 
easier to simply remove this portion of the recipient vena cava and replace it with 
the comparable segment of the donor liver's vena cava into which all of the 
hepatic veins empty (3). 
Operative survival with the complete canine replacement operation (Figure 
2) was not accomplished until a few days after I moved to Northwestern in June, 
1958, for a final 12 months of cardiovascular surgical training that was expected 
to culminate in an academic practice in thoracic surgery. Instead, 2 steps were 
taken during the summer of 1958 that ensured pursuit of the liver research for at 
least 5 years beyond completion of the thoracic residency. The first step was the 
submission of a 4 page NIH grant focused on metabolic studies in which liver 
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replacement was one of the experimental models. The second step was my 
nomination by Northwestern for a John and Mary Markle Scholarship. Here, the 
emphasis was radically different. 
Markle Scholar candidates were expected to identify an open-ended 
career objective. Ignoring advice to develop a "more realistic" project in the 
emerging field of open heart surgery, I proposed the life goal of clinical liver 
transplantation. In the autumn of 1958, I learned that the NIH grant would be 
fully funded for 5 years, and shortly thereafter that I had been selected as a 
Markle Scholar. The first phase of the canine liver project was nearly completed 
by the time I finished the thoracic residency and the dual revenue streams began 
on 1 July 1959. In addition, a second operation had been perfected in which the 
liver was transplanted as part of an allograft that contained all of the other intra-
abdominal viscera (Figure 3) (6,7). 
The magnitude of the Markle proposal should have been intimidating, but 
it did not seem so at the time. The slate of liver transplantation was nearly blank 
in 1958, but what had to be done was transparent: make the operation 
biologically sound, make it practical, and find a way to prevent allograft rejection. 
I was not the only person to think that way. Although I did not learn of it until a 
year later, Francis D. (Franny) Moore had begun independent efforts to replace 
the dog liver during the summer of 1958 at the Peter Bent Brigham Hospital in 
Boston (4,5) that continued until the mid,.1960s (87,88). 
Moore's transplant interests were not confined to the liver. This can be 
perceived most clearly by reading his book, Give and Take (89) and his 
autobiography A Miracle and a Privilege (90) written 4 decades later. 
Epitomizing his ubiquitous presence, Moore presided as chief of surgery at the 
Brigham over the clinical renal transplant trials of Murray and Merrill that yielded 
the world's first example in any species of ~ one year survival of an organ 
allograft (91). In this case, the kidney from a fraternal twin was transplanted to 
his irradiated brother on January 24, 1959, and functioned for the next 20 years 
without maintenance immunosuppression (Table 2). 
From my point of view, this faint signal that the genetiC/immunologic 
barrier to organ alloengraftment might be surmountable made the liver transplant 
objective less distant. It seemed almost providential that the 5-year Markle 
Scholarship and NIH funding (1959-64) for my liver project began a few months 
after the fraternal twin transplantation. The 5 years was equally split between 
Northwestern where I was elevated to a junior faculty position on 1 July 1959, 
and the University of Colorado where I was appointed Associate Professor of 
Surgery and Chief Surgeon at the Denver VA Hospital from November 1961. 
The Immune System and Its Control (Theme III) 
Until 1958-60 the only organ allograft whose unmodified rejection had 
been thoroughly studied was the kidney. Rejection to death of our canine liver 
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recipients usually occurred in 5 to 10 days (3). However, in rare outlyers in which 
the biochemical indices of rejection improved spontaneously, the liver allograft's 
dominant histopathologic findings by 3 weeks were those of repair and 
regeneration (92). These were the first recorded exceptions to the existing 
dogma (based on skin graft research) that rejection, once started, was 
inexorable. 
In the multivisceral grafts (Figure 3), the pathology was subtly different. 
Rejection of the various organs if they were part of the multivisceral graft was 
less severe than when the organs were transplanted alone. Moreover, there was 
overt evidence in recipient tissues of a graft versus host (GVH) reaction, but 
without a skin rash or other manifestations of graft versus host disease (GVHD) 
(7). The double immune reaction (host versus graft [HVGJ and graft versus host) 
exposed by those experiments was shown a third of a century later to be a 
feature of alloengraftment and acquired tolerance no matter what the 
transplanted organ (see later). 
Both my liver-alone and multivisceral transplant models were generally 
viewed as technical exercises of little if any scientific interest. One reason was 
the prevailing view that was concisely expressed in 1961 by the 1960 Nobel 
Laureate, F.M. Burnet in a New England Journal of Medicine review entitled, The 
New Approach to Immunology. The discouraging passage read: It... Much 
thought has been given to ways by which tissues or organs not genetically and 
antigenically identical with the recipient might be made to survive and function in 
the alien environment. On the whole, the present outlook is highly unfavorable to 
success" (93). 
I was poorly equipped to rebut this kind of opinion. My attempts in 
Chicago to use radiation therapy for canine liver transplantation in 1959-60 failed 
miserably (94). During this bleak time, however, it Was reported in a closely-
spaced succession of articles that 6 mercaptopurine and/or its analogue, 
azathioprine, were immunosuppressive in non-transplant (95,96), rabbit skin graft 
(97,98), and canine kidney transplant models (99,100). The most extensive 
kidney transplant experiments were done by the 30 year old English surgeon, 
Roy Caine (101) who began his studies at the Royal Free Hospital in London in 
1959 while still a registrar (resident). The work was continued in Boston with 
Joseph Murray after July 1960 (102). 
In 1961, Caine visited our laboratory in Chicago and described his results. 
Shortly thereafter, I moved to Colorado, after making the decision to develop a 
human kidney transplant program there with drug immunosuppression as a 
forerunner for the liver objective. This would be a bold step since the renal 
center at the Brigham was the only one in America at the time with an active 
clinical transplant arm. After demonstrating in parallel canine kidney and liver 
transplant studies of azathioprine that advances with either organ would be 
applicable to the other, we concentrated our immunosuppression research on the 
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simpler kidney mode\. Our most promising results were obtained by giving daily 
doses of azathioprine monotherapy before as well as after kidney transplantation, 
adding postoperative prednisone only when overt rejection developed. 
By the time the incremental drug protocol was taken to the clinic in the 
autumn of 1962, 6 renal allograft recipients treated primarily or exclusively with 
the total body irradiation protocol of Murray's fraternal twin case (see earlier) had 
either passed or would soon reach the one year survival milestone, including 2 
French patients to whom the donors were not genetically related (Table 2) 
(91,103-105). In addition, Murray had transplanted a deceased donor allograft in 
Boston on April 5, 1962, under azathioprine-based immunosuppression 
(106,107). The kidney was destined to function for 17 months and become the 
world's first to survive 2:: 1 year with a radiation-free (drugs-only) protocol. 
Enthusiasm generated by this last case was tempered, however, by the fact that 
the recipient was the only one of the first 10 in the Boston azathioprine series to 
survive longer than 6 months (details annotated in Ref 108). 
Some members of our Denver team concluded from this sobering news 
that our accrual of more renal transplant cases would be a futile and 
embarrassing undertaking. My counter argument was that our laboratory-based 
treatment strategy differed in many ways from the one used in the Boston 
protocol, including a role of prednisone equal in importance to that of 
azathioprine. The differences proved to be crucial. First in dogs, and then in 
human kidney recipients, the graded use of azathioprine and prednisone 
exposed the 2 features of the alloimmune response that provided the basis for 
the transplantation of all kinds of organs. 
The 2 phenomena were capsulized in the title of a 1963 report of the first-
ever series of successful kidney allotransplantations: "The reversal of rejection in 
human renal homografts with subsequent development of homograft tolerance" 
(8). The principal evidence that the allografts (then called homografts) had 
somehow induced variable donor specific tolerance was that the reversal of 
rejection frequently was succeeded by a time-related reduction, or in some cases 
elimination, of the need for maintenance immunosuppression. In fact, 8 
recipients in the 1962-64 Colorado series of 64 still bear the world's longest 
functioning renal allografts, 45 or more years later (109). Six of the 8 have been 
off all immunosuppression medications for 12 to 46 years. 
Transplantation Outcomes With the Forerunner Kidney (Theme IV) 
The > 70% one year patient and renal graft survival in our seminal 
Colorado series (110,111) exceeded my own expectations, and was not 
considered to be credible until David Hums in Richmond and others added their 
confirmatory experience. The world-wide reaction was remarkable. In the spring 
of 1963, there had been only 3 clinically active renal transplant centers in North 
America (Boston, Denver, and by now Richmond) and scarcely more in Europe. 
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One year later, 50 new renal programs in the United States alone were either 
fully functional or were gearing up. 
In reflecting back a dozen years later on the kidney transplant revolution of 
1962-64, I began my founding lecture for the American Society of Transplant 
Surgeons (ASTS) with the comments that: "From time to time, a news story 
appears about the birth of a husky, full-term baby, much to the amazement of the 
chagrined mother who had not realized that she was pregnant. Mother surgery 
seemed to have been thus caught by surprise when clinical transplantation burst 
upon the scene in the early 1960s" (112). 
Issues of humanism (Theme V) 
Liver transplantation was swept up in the 1962-64 kidney momentum. 
However, there were many reasons to be cautious, not the least of which were 
social, ethical, and legal concerns. Throughout 1962, I discussed these issues 
personally with key non-university persons: the Colorado Governor (John Love), 
our United State Senator (Gordon Allot), the Denver Coroner, the Chief Justice of 
the Colorado Supreme Court, and clerical leaders. All ultimately expressed 
support. Resistance within the University was dealt with by the legendary 
medical school dean, Robert J. Glaser, and the University Chairman of Surgery, 
William R. Waddell. 
Unprecedented technical challenges were expected. The liver 
replacement operation, which was difficult even under the optimal circumstances 
of the animal laboratory, predictably would be harder in recipients with portal 
hypertension and other pathophysiologic and anatomic changes of chronic liver 
disease. In the absence of artificial organ support, failure of the hepatic graft to 
promptly function would be tantamount to death. Finally, how could immediately 
life-supporting deceased donor livers be obtained in an era in which death was 
defined as the cessation of heart beat and respiration? 
These questions and issues mandated consideration of the less draconian 
auxiliary hepatic transplant operation of Welch that mightaliow recipient survival, 
even if the graft failed. This option was undermined when the rapid atrophy of 
auxiliary livers that previously had been ascribed to rejection in unmodified dogs 
(86,113), was shown to be equally severe in animals in which rejection was 
prevented with azathioprine (11). The die was cast for the liver replacement 
(orthotopiC) option. 
THE FIRST HUMAN LIVER TRANSPLANTATIONS 
Liver replacement was carried out in 7 deceased donor liver recipients 
between March 1963 and January 1964: 5 in Denver (cases 1-4 and 6), Boston 
(case 5 by Moore's team) and Paris (case 7) (Table 3) (10,11,88,114). All 7 
patients died, 2 during the operation and the other 5 after 6.5 to 23 days. Neither 
primary non-function nor uncontrolled rejection of the grafts were lethal factors in 
any of the failures. 
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At autopsy of the 4 Denver patients who survived the operation, 
pulmonary emboli were found that apparently had originated in the bypass tubing 
used to decompress the blocked systemic and splanchnic venous beds during 
the removal and replacement of the native liver. Ironically, the bypass which had 
been an essential component of the canine operation, is not mandatory in most 
human recipients, or even in dogs if venous col\ateralization is encouraged by 
bile duct ligation a month in advance (115). 
By the time our fourth and fifth liver recipients were reported to the 
American Surgical Association in April 1964 (11), all clinical liver transplant 
activity had ceased in what would be a voluntary 3-1/2 year worldwide 
moratorium. The self-imposed decision to stop did little to quiet polite but 
unmistakably disapproving discussions of an operation that had come to be 
perceived as too difficult to ever be tried again. 
THE MORATORIUM 
In effect, it now would be necessary to return to ground zero and 
reexamine all 5 of the themes of Table 1. The central assumption of Theme I 
had been that portal venous blood contained hepatotrophic molecules. The 
hypothesis was consistent with our results in 1958-60 in non-immunosuppressed 
canine recipients of replacement livers (3), and especially with the acute atrophy 
of Welch's auxiliary grafts in azathioprine-treated dogs (see earlier, and Ref 11). 
The possibility was now explored of providing the auxiliary allografts with direct 
access to the portal molecules (116). 
But what were the hepatotrophic factors? Using double liver fragment 
non-transplant models derived from Welch's auxiliary liver operation (Figure 4), it 
was proved during and after the moratorium that insulin is the principal (although 
not the only) hepatotrophic molecule in portal blood; that insulin is avidly 
removed by the liver; and that its primary passage through the hepatic 
microvasculature is crucial for the maintenance of liver size, ultrastructure, 
function, and the capacity for regeneration (27,28,116-122). When other 
molecules subsequently were identified that had insulin-like or diametrically 
opposite effects (Table 4), hepatotrophic physiology blossomed into multiple 
research areas of metabolism and regenerative medicine (123,124). 
Although the moratorium studies did not support reconsideration of 
auxiliary liver transplant trials, they added a new dimension to the operation of 
portacaval shunt which had been used primarily to treat complications of portal 
hypertension. With the demonstration of the profound effects of portal diversion 
on protein, carbohydrate (119), and lipid metabolism (121), portacaval shunt was 
used to favorably alter the course of 3 categories of inheritable metabolic 
disorders: glycogen storage diseases (125,126), familial hyperlipoproteinemia 
(127,128), and alpha-1-antitrypsin deficiency (129,130). The dramatic 
amelioration of the pathophysiology of these diverse conditions (e.g. 
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hyperlipoproteinemia, Figure 5) presaged their definitive correction with liver 
replacement (see next section). 
Themes II (the surgical operations) and 111 (immunology) were pursued 
with both kidney and liver canine transplant models. These efforts included the 
construction and testing of equipment with which livers could be preserved for 
one or two days (131), the experimental development and clinical introduction of 
antilymphoid globulin (ALG) (13,132), and the demonstration that 
immunosuppression-aided organ tolerance was more frequently induced by the 
liver than by the kidney (12). In addition, studies of our burgeoning human 
kidney recipient population clarified the role of HLA matching in all kinds of organ 
transplantation (14). 
Activity also had intensified on the humanism issues (Theme V). The 
agenda items at medical ethics conferences in 1966-67 (15,16) included human 
experimentation, living organ donation, informed consent, and the equitable 
allocation of organs. The most definitive consequence of these discussions was 
an evolving consensus that the end of life was more appropriately defined by 
brain death than by the previous criteria of cessation of heart beat and respiration 
(18). 
THE LIVER TRANSPLANT BEACHHEAD 
Despite these accomplishments, confidence about our impending liver trial 
was nowhere near the level that had existed during the run up to the 1963 
attempts. The legacy of doubt from the earlier failures was cancelled by a critical 
new factor. This was the arrival in 1966 of Carl Groth, a 32 year old Fulbright 
Fellow from Stockholm who joined all of the thE?matic developments and became 
a key member of both the donor and recipient teams. With Groth's leadership, 
multiple examples of prolonged human liver recipient survival were produced in 
1967 (Figure 6), using triple drug immunosuppression (azathioprine, prednisone, 
and ALG) (17). 
The first Denver successes were bolstered by the opening in 1968 of a 
second clinical liver program by Roy Caine in Cambridge, England (133), 
following preclinical studies in outbred pigs (21,134). The early trials were 
described in my 1969 book entitled, Experience in Hepatic Transplantation (22), 
based on our first 25 human liver replacements and 8 performed elsewhere (4 by 
Caine). Collateral support was provided with the use of the same 
immunosuppression regimen for the first successful human heart, lung, and 
pancreas transplantations (135-137) (Table 5). However, the promise of the non-
renal procedures, and even of deceased donor kidney transplantation, was 
unfulfilled for the next dozen years because of immunosuppression-related 
morbidity and mortality. 
Half or more of the liver recipients treated during this time died within the 
first post-transplant year. The most encouraging observation was that many 
FINAL 11 Hepatology 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
Hepatology 
patients who survived to this milestone were quietly compiling years of good 
health thereafter (64,155) (Figure 7). Despite deepening suspicion that progress 
in the whole field of organ transplantation had permanently stalled, the new 
French and German liver teams of Henri Bismuth and Rudolf Pichlmayr joined 
the Denver-Cambridge (Eng) alliance in the early 1970s, followed later in the 
decade by the Dutch group of Rudi Krom. Much of the medical-scientific, logistic, 
and administrative framework of hepatic transplantation that exists today was 
developed by the 5 mutually supportive liver centers during the frustrating period 
between 1969 and 1979. 
Most of the indications for liver transplant candidacy were obvious, 
including inheritable disorders with a definitive biochemical explanation (e.g. 
Wilson's disease [23]). The acid test of liver transplantation ultimately would help 
elucidate the mechanisms or pathophysiology of less well-understood inborn 
errors: e.g. the 3 diseases that were palliated by portacaval shunt (see earlier). 
Four patients with alpha-1-antitrypsin deficiency underwent liver transplantation 
between 1973-1977 (138,139). Liver replacement for treatment of glycogen 
storage disorders (140,141), hyperlipoproteinemia (44,45), and a growing 
panoply of other metabolic diseases awaited better immunosuppression. 
THE LIVER AVALANCHE 
Improvements in therapy were heralded in 1979 by Roy Caine's report of 
cyclosporine-based immunosuppression in 34 patients, including two liver 
recipients (33). The side effects of cyclosporine precluded its use as a single 
agent. However, when it was substituted for azathioprine in our two- or three-
drug therapeutic algorithm that included dose-maneuverable prednisone (34), 
cyclosporine's full potential was realized. Kidney recipients were the first to be 
treated with liver recipients close behind. Eleven of our first 12 liver recipients 
treated in Colorado with cyclosporine-based immunosuppression during 1979-80 
survived for more than one year (35). 
More experience in 1981-82 (now in Pittsburgh) was confirmatory. In 
December 1981, these findings were reported to C. Everett Koop, the United 
States Surgeon General, who initiated a Consensus Development Conference 
for liver transplantation that would include input from the European centers. Prior 
to the Conference, I prepared a summary of our experience for presentation on 
November 1, 1982, at the American Association for the Study of Liver Disease 
(AASLD), and publication in Hepatology the same month (36). An updated 
version was presented to the Consensus Development Conference on June 20-
23,1983. 
The consensus committee concluded that liver transplantation had 
become a "clinical service" as opposed to an experimental procedure (38). The 
resulting world-wide stampede to develop liver transplant centers was even more 
dramatic than that of kidney transplantation 20 years earlier. Only 6 years after 
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the Consensus Conference, a 17 page article equally divided between the 
October 12 and October 19 issues of the New England Journal of Medicine (142) 
contained a opening statement that, "The conceptual appeal of liver 
transplantation is so great that the procedure may come to mind as a last resort 
for virtually every patient with lethal hepatic disease." It already was evident that 
the need for these operations would greatly exceed both an identifiable source of 
organs and those qualified to transplant them. 
A significant number of the next generation of liver transplant leaders who 
flocked to Pittsburgh for clinical training during the 1980s were non-surgeons. 
Their primary connection was with David Van Thiel (Figure 8), the brilliant 
gastroenterologist who became a founding doyen of transplantation hepatology 
along with his EngUsh counterpart, Roger Williams of the Cambridge-King's 
College program.': During this volatile period, preclinical studies of tacrolimus 
were begun that wouldl~ad to its substitution for cyclosporine (56,57) with fast-
track FDA approvalin,Noyember1993. With tacrolimus, the multivisceral and 
intestine-alone transplanf/~rocedures developed 3 decades earlier in dogs 
(Figure 3) achieved the statu$,of,? genuine "clinical service" (61,62). The timing 
was perfect. With arrival of niY65th birthday in 1991, I retired from active surgical 
practice. 
THEMATlC.Ei311..9GUE: 1991 - 2009 
Most of the advances in liver transwlantation during the succeeding 18 
years (Table 1) have been derivative from"eQ;tliei' work including the use of partial 
livers from deceased or living volunteer donors. However, the antecedent 
contributions with which the taxonomical foundatidn,of organ transplantation was 
built have been obscured with the advent of the WOrld Wide Web (www). Many 
of the referenced articles of the foregoing narrative cannot be accessed online in 
full text, and some have become invisible. With(trre dearth of electronic 
information from before the 1990s and the conveniehceof citing easy internet 
finds, the recent literature has been replete with obseryt;ations, events, and 
concepts that were described more clearly years or decades before. 
Nevertheless, there have been new trends in organ transplantation, 2 of which 
were driven mainly by the liver. 
The Exegesis Of Alloengraftment 
A major gap in immunology (Theme III) when I stopped surgical practice 
was the inability to explain why organ transplantation had been possible. 
Because organ recipients were not infused with donor leukocytes, it became 
dogma by the early 1960s that the donor leukocyte chimerism associated with 
acquired tolerance in experimental models was not a factor in organ engraftment. 
The dogma was not challenged until we discovered small numbers of 
multilineage donor leukocytes (microchimerism) in the blood or tissues of all 
FINAL 13 Hepatology 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
Hepatology 
studied long-surviving liver, kidney, and other or~an recipi,ents ESPIS4~14PFK 
These findings in 1992-93, and an array of supporting expenmental stud~es In 
congenic rat (144-150) and mouse models (151-154) mandated a change In the 
previously perceived landscape of transplantation immunology. 
It was proposed (63,64,155,156) that organ transplantation was the 
equivalent of a bone marrow transplantation. The key step leading to rejection, 
or alternatively alloengraftment, after both kinds of transplantation was 
hematogenous migration of leukocytes (including stem cells [157-159]) to the 
recipient's lymphoid organs (Figure 9). Otherwise, the presence of the allograft 
would not be recognized: Le. the "immune ignorance" (160,161) first described in 
a transplant model by Clyde Barker and Rupert Billingham 42 years ago. The 
seminal mechanism;:of. alloengraftment was exhaustion-deletion of the T cell 
response (162,163)",'induced at the host lymphoid sites by the invading cells 
(Figure 9). Becaus~IDthe migrant donor leukocytes are immune competent, 
successful alloengraftrqent)nvolved a double immune reaction in which immune 
responses of coexisting 'dOnor and recipient celis, each to the other, were 
reciprocally exhausted an<:tdeleted under a protective umbrella of 
immunosuppression (Figure,H)}. 
Our interpretation of thelTliGtochimerism was at first highly controversial 
(164,165) because it was incompatibl~with multiple theories and hypotheSiS that 
made up much of the base of transpl?:.n,t immunology. Resistance to the new 
concept was eroded when Rolf Zinkern'a-gel inZurich independently proposed an 
explanation of acquired tolerance to pathq~~:psDIthat was essentially the same as 
that of our allotolerance paradigm. In th~E1 ~TEssI Zinkernagel and Doherty had 
demonstrated that the MHC-restricted cytolytic., T cell response induced by 
noncytopathic microorganisms was the sarri~D;DasI that induced by allografts. 
These studies were done in highly controlled expK~r!mb:lntal models of infection 
with the lymphocytic choriomeningitis virus (LCMV)' and other intracellular 
parasites (166). Their subsequent investigations oftoJetance were done with the 
same models and described in 4 landmark articles betWeeo'1993 and 1997 (167-
170). 
With recognition that the Pittsburgh and Zurich investigations were on 
parallel pathways, a joint author review was published in a December 1998 issue 
of the New Eng/and Journal of Medicine in which analogous scenarios were 
described of transplantation and pathogen-specific infections (e.g. chronic 
rejection vis a vis chronic viral hepatitis) (65). The concept developed from 
transplant and infection models was generalized in the following way: "The 
migration and localization of antigen govern the immunologic responsiveness or 
unresponsiveness against infections, tumors, or self --- and against xenografts or 
allografts" (65). In this view, all outcomes in the divergent circumstances of 
transplantation including those of microchimerism (150,171,172) were 
determined by the balance established between the amount of mobile donor 
leukocytes with access to host lymphoid organs and the number of donor-specific 
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cytolytic T-cells (CTL) induced at the lymphoid sites (Figure 11, inner graphic) 
(65). 
Long term organ alloengraftment with this generalizable paradigm, was a 
highly variable form of leukocyte chimerism-dependent tolerance, the 
completeness of which could be inferred from the amount of immunosuppression 
necessary to maintain stable function and structure of the transplant (Figure 11). 
In a second article with Zinkernagel, the mittsburgh~wurich immunologic paradigm 
provided a road map for improved therapeutic strategies of transplant patient 
management based on 2 principles: recipient pretreatment, and the least 
possible use of post-transplant immunosuppression (68). When applied clinically 
for different kinds of organ transplantation (69), these strategies have minimized, 
or in some cases eliminated, the burden of chronic immunosuppression (173-
178). More rational approaches also were developed for the treatment of 
opportunistic infections/caused by noncytopathic microorganisms (70,168,179). 
Reporting of Transpla.,tation Outcomes (Theme IV) and Equitable Organ 
Allocations (Theme V) 
A second trend coincided with and was empowered by the rise of the 
internet. One of the mandatesot the 1984 National Transplant Act was the 
formation of an organ procuremEtht and transplantation network (OPTN). 
Another was the development ofa~9i~ntific registry of transplant recipients 
(SRTR) with which patient and graft suivival.90u1d be quantified from center to 
center along with center-specific parame!~t~KIAfter the Department of Health 
Resources and Services Administration (OijHS) awarded the contract for both 
functions to the United Network of Organ Sh'llrjrtQ(UNOS), disputes about organ 
allocation within the appointed UNOS commifte.a:prevented the development of 
the required plan. In order to avoid a UNOS defal,1ltpf cpntract, a document was 
pieced together from 2 articles In Press describing the renal (180) and non-renal 
(181) distribution systems already in place in Pittsburgh; 
In the contract derived from these manuscripts andpr~sented to DHHS on 
the eve of the deadline, the overwhelming factor forliVef distribution was 
recipient urgency of need (181). In contrast, time waiting dominated kidney 
distribution with major credit for HLA matching only when this was complete 
(180). Although these policies were accepted by DHHS and provisionally 
implemented in November 1987, they were widely abridged (182) until the final 
regulations were issued by DHHS on April 2, 1998. During the chaotic 
intervening decade (see Supplementary Index for a cryptic description of the 
"liver wars"), UNOS led the opposition to adoption of the regulations and withheld 
access to SRTR. A Lancet Editorial during the heat of the debates suggested 
that: "UNOS would better serve the transplant community if it abandoned its 
stance and began working with DHHS to draw up allocation policies that are 
practical and fair (183)". 
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One of the most contentious issues was the conclusion in a large 
Pittsburgh study published in 1994 that liver transplantation performed too early 
was associated with a net loss of recipient life years (184,185). These findings 
led to retention of the "sickest first" policy in both the provisional and final DHHS 
rules for liver allocation. In the meanwhile, the continued resistance to release of 
center-specific data, as well as inaccuracies and inconsistencies in the first 
SRTR reports (1992, 1995, 1997), led to transfer of SRTR management to the 
University of Michigan-based Arbor Research Collaborative for Health. An Arbor 
multicenter study in 2005 confirmed the original Pittsburgh findings about the 
timing of liver transplantation and came to the same policy recommendations 
(186). 
Until now, s~ccess with liver transplantation has been judged largely by 
relatively short tel"mp.ath:mt and graft survival. A more complete profile has been 
made possible by the use of the treatment-based evaluation system of Clavien in 
which the rate and seYerityof complications (including death) are quantified with 
a 5-tier scale (71). ThevalU'e of this objective assessment was exemplified by a 
recent Pittsburgh study of rightlopar living donor liver transplantation (187). The 
Clavien metric is applicabletS:D~a!lDkinds of organ transplantation, and has been 
generalized to other surgical and medical procedures (188). 
" ,. 
CONCLUSION 
Liver transplantation began with almost no resources at the same time as 
the tentative first steps were taken to land.a'ihi:m on the moon. Because human 
lives would be at stake, both objectivesDDtl~cba sacramental element from the 
outset: i.e. a solemnly binding commitmentto,J:)er.fection. A need for that pledge 
still exists. 
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TABLE 4 
HEPATOTROPHIC FACTORS REVEALED BY 1994 
WITH PORTAL DIVERSION, DOUBLE LIVER 
* FRAGMENT, OR PARTIAL HEPATECTOMY MODELS 
Annotated in Hepatology 20:747-757,1994 (Ref 124) 
Hepatotrophic 
Hormones: 
Insulin 
Growth factors: 
Cytosol substrate and ALR 
IGF II 
TGF-a a 
HGF a 
Immunosuppressants: 
Cyclosporine 
Tacrolimus 
Immunophilins: 
FKBP'2 
Anti-hepatotroph ic 
Growth factors: 
qdc~b 
Immunosuppression: 
Rapamycinb 
*It is noteworthy that numerous humeral and cellular mechanisms involved in liver size homeostasis 
and regeneration (not shown here) are the same as those involved in immunologic responsiveness 
(rejection) and unresponsiveness (tolerance). 
aMitogenic in tissue culture 
blnhibitory in tissue culture 
ORGAN 
Kidney 
Liver 
Heart 
Lung* 
Pancreas** 
TABLE 5 
THE DOMINO EFFECT IN 1968-69 OF THE 1967 
FIRST SUCCESSFUL HUMAN LIVER TRANSPLANTATIONS 
CITY DATE PHYSICIANI 
SURGEON 
Boston 1/24/59 Merrill/Murray 
Denver 7/23/67 Starzl 
Cape Town 1/2/68 Barnard 
Ghent 11/14/68 Derom 
Minneapolis 6/3/69 Lillehei 
REF 
91 
17 
135 
136 
137 
*Patient died after 10 months; all others in table lived >one 
year with functioning graft. The first >one year survival of 
isolated lung recipients was not reported until 1987. 
**Kidney and pancreas allografts in a uremic patient. 
FIGURE LEGENDS 
Figure 1 --- Auxiliary liver homotransplantation in dogs (the Welch 
procedure). Note that the portal venous inflow of the extra liver is from the 
inferior vena caval bed while the native liver retains a normal blood supply. It 
was suspected from the beginning that this was a major flaw in the design of the 
procedure. From: Ann Surg 160:411-439, 1964. 
Figure 2 -- Complete liver replacement in the dog circa 1958-9. The fact 
that this was a canine rather than a human operation is evident only from the 
small multiple lobes of the allograft and the biliary drainage with 
cholecystoduodenostomy. In my first report (3), an "outflow block" syndrome 
resembling endotoxin shock was described if donor body weight was less than 
half that of the recipient (one cause of today's "small for size" syndrome). 
Figure 3 --- Bottom Center: Multivisceral allograft transplanted in dogs in 
1959 (6,7) and in humans for the first time 3 decades later (46). With removal of 
different organs from the common vascular stem, this original procedure has had 
many subsequent variations. Lower Left: Liver-intestinal transplantation (47,62). 
Top Middle: Cluster of upper abdominal organs (55). Right: Mid gut organs 
except the liver. From: Liver Transplant & Surg 4:1-14, 1998. 
Figure 4 --- The double liver models that led to progressively precise 
identification of the hepatotrophic factors that influenced liver size, ultrastructure, 
function, and the capacity for regeneration: (A) Welch's index operation of 
auxiliary liver allotransplantation (see also Figure 1); (B) non-transplant split liver 
model that differentiated the effect on the liver of systemic venous (vena caval) 
versus splanchnic (portal) blood; (C) separation with the double liver fragment 
model of the qualities of venous blood from the upper and lower abdominal 
viscera; and (0) selective infusion of candidate hepatotrophic molecules into one 
or the other of 2 liver fragments, both of which had an arterial supply only. From: 
Liver Transplant & Surg 4: 1-14, 1998. 
Figure 5 --- The dramatic effect of portacaval shunt on serum cholesterol 
concentration in a child with homozygous familial hyperlipoproteinemia. These 
observations (24) and canine studies of lipid synthesis with the models shown in 
Figure 4 (25) suggested that the liver was the principal site of cholesterol 
homeostasis. Although we considered familial hyperlipoproteinemia. to be a 
candidate disease for liver replacement from the mid 1970s, this was not 
accomplished until February 14, 1984 (44,45) by which time more evidence that 
this was an appropriate step was obtained in New York, Bethesda, and Dallas. 
Interactions over more than a dozen years between experts in cholesterol 
metabolism in these cities and the author (TES) are described in the chapter 
"The Little Drummer Girls" of The Puzzle People (128). From: Lancet 2:940-
944,1973 
Figure 6 --- The first 3 human recipients with prolonged survival following 
liver replacement in July and August, 1967. The adult, Carl Groth, was a 
Swedish surgeon-in-training whose tenures in Denver as a Fulbright Scholar 
(1966-68) and faculty member (1970-71) were near the beginning of his 
Olympian career. After returning to Stockholm to occupy a Chair in 
transplantation surgery created for him at the Karolinska Institute, Groth 
developed the multiorgan transplant program that produced the first liver 
transplantations in Sweden. His numerous honors include the King's Medal of 
his country and the Medawar Prize, the highest distinction of the international 
Transplantation Society. 
Figure 7 --- World's longest surviving liver recipient whose 40th post-
transplant anniversary will take place January 22, 2010. The primary disease 
diagnosis was biliary atresia, but the right lobe of her excised liver contained an 
incidental 2.7 x 1.8 centimeter hepatoma. The serum alpha fetoprotein level was 
6 mg/cm at one post-transplant month, trace-present at 4 months, and 
undetectable since (Ref 189). The patient's companion, now a retired United 
States Marine, is her husband of many years. The statue behind them is 
Roberto Clemente (1934-1972), the greatest baseball right fielder of all time who 
was killed bringing food by air flight to victims of the catastrophic Nicaraguan 
earthquake. 
Figure 8 --- David Van Thiel (1941-), gastroenterologist-hepatologist 
without whose herculean efforts, the University of Pittsburgh liver transplantation 
program could not have been established. 
Figure 9 --- The cell migration and localization of organ and bone marrow 
cell transplantation. Organs (here a liver) are composites of architecturally fixed 
cells and mobile multilineage cells of bone marrow origin ("passenger 
leukocytes") that include pluripotent hematolymphopoietic stem cells (157-159). 
Within minutes after organ transplantation, the passenger leukocytes simulate a 
bone marrow cell infusion by migrating selectively to recipient lymphoid organs 
where they induce the depleted antidonor T cell response. Although the clonal 
response normally destroys the invading donor cells and their outlying source 
organ (rejection), the response may be exhausted and deleted if it is too weak to 
eliminate the invading donor cells during the first few weeks of maximal cell 
migration. Perpetuation thereafter of survival of the bystander organ allograft 
requires persistence of enough donor leukocytes to maintain the initial 
exhaustion-deletion. Importantly, the invading donor cells are immune 
competent and their response against the recipient also must be exhausted and 
deleted for a successful transplant outcome (see Figure 10). 
Figure 10 --- The kinetics of immunosuppression-aided exhaustion and 
deletion of the contemporaneous host versus graft (HVG, upright curve) and graft 
versus host (GVH, inverted curve) responses in organ recipients following the 
cell migration shown in Figure 8. Although HVG is the dominant response in 
most organ recipients (expressed as rejection), serious or lethal GVH reactions 
(expressed as graft versus host disease [GVHOJ) are not rare in recipients of 
lymphoid-rich organs (liver, intestine). In naturally immune deficient or 
cytoablated bone marrow cell recipients, GVHD is avoided by using 
histocompatible (HLA-matched) donors. Therapeutic failure after either organ or 
bone marrow cell transplantation implies the inability to control one, the other, or 
both of the responses. From New Engl J Med 339:1905-1913,1998. 
Figure 11 The many faces of transplantation tolerance. 
Outer Circle: The continuum of experimental and clinical donor leukocyte 
chimerism-associated tolerance models that can be traced back to observations 
in 1945 in freemartin cattle (upper left) whose fused placentas permitted fetal 
cross-circulation, blood chimerism, and reciprocal immune nonreactivity. 
Inner Graphic: Permutations of tolerance defined as balances between 
persisting migratory donor leukocytes and the number of antidonor T cells 
undergoing steady state exhaustion-deletion. The achievement of balances and 
the resulting clinical phenotypes are influenced by the dose, type, and timing of 
immunosuppressive therapy and by the dose, type, timing, route, and localization 
of the migrant donor cells. The single most important factor leading to the 
macrochimerism of bone marrow cell transplantation versus the microchimerism 
of most organ (and composite tissue) recipients is enfeeblement of recipient 
immune reactivity before the arrival of donor cells in the first instance and after 
their arrival in the second. The non-specific potential "stabilizing factors" in the 
left-directed arrow above the human silhouette include special cells (e.g. T-
regulatory), enhancing antibodies, graft secretions, and endogenous 
cytoprotective molecules. 
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SUPPLEMENTARY APPENDICES 
1. Supplementary Appendix #1: The Neuroscience Interval 
Item A: A 1991 letter written by the author (TES) in response to a request 
by Dr. Louise Marshall who was writing a history of the UCLA Brain 
Institute. 
Item B: A related letter written in December 1951 from Professor H.W. 
Magoun to Dr. Alfred Blalock, supporting the candidacy of TES for a Johns 
Hopkins Internship. This letter was found by Dr. Henry T. Bahnson in 1989 
when he was cleaning out his office after retiring from the Surgical Chair at 
the University of Pittsburgh. Dr. Bahnson did not know who was 
responsible for the underlines, but thought that it probably was Dr. Blalock. 
2. Supplementary Appendix #2: Dust cover written by TES for the book, 
"Defying the Gods" by Scott McCartney (Macmillan Publishing Company, 
1994) based on the program founded by Dr. Ooran Klintmalm (a former 
fellow of Dr. Starzl) at Baylor University Hospital, Dallas. 
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University of Pittsburgh 
SCHOOL OF MEDICINE 
Department of Surgery 
September 16, 1991 
l 
Louise H. Marshal~ 
University of California, Los Angeles 
Brain Research Institute 
Center for the Health Sciences 
10833 Le conte Avenue 
Los Angeles, CA 90024-1761 
Dear Ms. Marshall: 
I will try to touch on the issues in your letter to me 
of August 23, 1991. Please bear in mind that I have not 
worked in neurophysiology for more than 40 years. 
Consequently my perspective never matured beyond the 
primitive state of knowledge which existed in ~949-19R1K I 
made no recent effort to educate myself about subsequent 
developments, fearing that this would change my memory of 
now-distant events. In addition, I would have to be re-
educated to comprehend the more sophisticated later 
literature. 
By coincidence, I wrote an autobiography last January 
which was written about transplantation, primarily for the 
lay public rather than the profession. I hope that the book 
will be published in 1992 in English, at the same time as 
translated Italian and Japanese versions. In it, Chapter 3 
(pages 30-47) is concerned mostly with the time spent during 
1949-1951) in Magoun's Northwestern and UCLA (Long Beach VA) 
laboratories. 
If you are interested, Chapters 19-21 have the inside 
story of my near move to UCLA, 30 years later. Paul 
Terasaki and Jim Maloney were major figures during this 
·latter time, and of course I have sent them the book for an 
accuracy check which it passed. Finally, almost all of 
Chapte= 12 is about Paul Terasaki in the 1965-1970 era. 
Magoun was a legendary figure at Northwestern where 
Neuroanatomy was taught separately from gross anatomy. The 
course was under Magoun's direct and very detailed 
supervision. Some of the men who later helped create your 
Brain Institute were at Northwestern at the time, although 
most of them did not playa large role in Magoun's 
neuroanatomy course and were not part of Magoun's nuclear 
research group. Included were Earl Eldred and Bill (Robert 
w.) Porter. Eldred and Porter .did Ph.D.'s in the Department 
of Anatomy, but under the supervision of other faculty 
members. 
Other than Magoun, the most senior person in the 
official Neuroanatomy section was Ray Snider whose interest 
was highly focused (some said monolithically so) on the 
cerebellum. Eldred's main research was with him. Snider 
did not have the vast range of knowledge possessed by 
Magoun, nor the creativity. These deficits, and I emphasize 
that the term was relative only to the luminescence of 
Magoun, prompted invidious comparisons between the two which 
must have undermined Snider's self confidence and made his 
life miserable. He seemed easily irritated, always near the 
explosion point. 
Bill Neimer was next in the seniority line. with his 
sunken eyes, raven black hair, and gaunt frame, he sometimes 
resembled a cadaver when he was immObile, or Boris Karloff 
(which is what the stUdents nicknamed him) when he moved. 
The reality was that he was just about the kindest and most 
gentle man whom I have ever met. When Magoun went to 
California, Bill Neimer took a faculty appointment at 
Creighton university in Omaha --- about 90 miles from my 
home town of Le Mars, Iowa. Whenever I was in Omaha during 
the succeeding years! I visited him. He seemed very happy 
there. 
Magoun's attention to his teaching responsibilities was 
greater than I have ever witnessed at any level of the 
education process. He gave most of the formal lectures in 
his neuroanatomy course, and each one was a masterpiece. 
Scheduled for one hour, the talks lasted exactly 55 minutes, 
and always were accompanied by beautiful visual aids. Until 
I worked with him in the research laboratory, I did not know 
that he wrote these lectures and memorized them with the 
same care as he might have taken for a plenary address at a 
major international congress. In addition, he always was 
present for the laboratory sessions, and his final 
"practical" examination, complete with dozens of specimens, 
was the supreme event of the semester. 
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I was a good student generally, and perhaps especially 
so in neuroanatomy. Because of his attention to the 
students, Magoun was aware of this. In the spring of 1949, 
toward the end of my sophomore year, he asked me if I wanted 
to be a summer research fellow. For the personal and 
consequent economic reasons which I described in Chapters 2 
and 3 of my autobiography, I was looking for a job which 
would allow me to stay in chicago instead of going home to 
Iowa. During the previous summer, I had worked as a 
copywriter at the chicago Tribune where I was invited, and 
even recruited, to return for a much higher salary. 
Magoun's advice was never to make a decision about work 
which was based on money. As a consequence, I joined him to 
continue the work on the reticular formation which he had 
begun with Giuseppe Moruzzi. 
By the time I came in May 1949 to Magoun's 7th floor 
laboratory in the Montgomery Ward Building, his foremost 
collaborator, Giuseppe Moruzzi had returned to Italy. I had 
seen Moruzzi from time to time in the preceding year and was 
left with an impression (which probably is wildly at 
variance with the facts) of a youngish, slightly portly, 
very active and intense individual with hawk-like features 
and an army style haircut. Leon Schreiner, the budding 
neurosurgeon who did the chronic experiments of reticular 
formation ablation with Don Lindsley (motor and sensory 
both), was still in evidence, largely as an observer of 
previously operated cats which were a miserable lot. 
Schreiner had the attributes of a movie star because of 
his good looks, long wavy hair, and a short but powerful 
build. He also had a dominant and engaging personality. 
His destiny was to be in University life, but somewhere 
along the way this was derailed. I think that he later 
worked at Walter Reed Hospital with David McRioch, but after 
that he went into the private practice of neurosurgery in 
Cheyenne, wyoming. About 15 years later, when I was Chief 
of Surgery at the Denver VA Hospital I saw him again. He 
seemed bitterly unhappy, not only about his professional 
world, but also in his personal life. I was alarmed, but 
after this I lost track of him. 
It was my misfortune not to have more than casual 
contact with Don Lindsley either in Chicago or California. 
Although I met Lindsley in Chicago, his work with Magoun 
appeared to have come to a hiatus at the time, and of course 
his arrival at UCLA was not long before the conclusion of my 
visit there in the spring and summer of 1951. Looking back 
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on it, I fit into a hole between Lindsley's collaboration 
with Magoun at Northwestern, and resumption of these joint 
Magoun-Lindsley activities in Los Angeles. The consequence 
is that I undervalued Lindsley's two papers in EEG Clin 
Neurophysiol, although I always cited them. Last week, I 
reread them for the first time in 40 years and realized that 
they were magnificent. 
There were other people at Northwestern whom I should 
mention. John Brookhart was in the Department of 
Physiology, where he taught neurophysiology as if it were in 
a different universe than Magoun's course. Here also, I 
failed to appreciate Brookhart's distinction until later 
when I spent the summer of 1951 with Brookhart's star pupil, 
Dave Whitlock. 
I never met Bowden and Knowles who were the "mystery" 
authors on the three seminal papers from Northwestern which 
appeared in 1949 in EEG Clin Neurophysiol. Wendell Krieg, a 
neuroanatomist who published books with artistic 
stereoscopic reconstructions of the brain, worked on a 
higher floor of the Montgomery Ward Building, but he might 
as well have been on Mars. There was a very cool interface 
between Magoun's group and Krieg's. 
My view of the magical environment of Northwestern in 
1949 was that Magoun was the shark under whose fins we all 
swam. Magoun already was the master of the reticular 
formation because of his work on the extrapyramidal motor 
system. The classic monograph on this subject by Ruth 
Rhines and Magoun had been published recently by Charles C. 
Thomas. The frontispiece was a picture of a man with 
hemiplegia. Magoun used the tragic photo to begin his book, 
and the first line of the text (which I cite from memory, 
probably with minor accuracies) read "In an autumn that is 
appropriately sere etc." 
What followed was a description of the partially 
paralyzed patient, but what stuck was the first line which 
reminded me of the beginning of Stephan Crane's famous story 
in which the survivor described his first impression of 
seeing muddy waves against the yellow sky. I realized that 
Magoun was an artist. Thereafter, it was easy to recognize 
what he had written, no matter who the ostensible first 
author was. I remember resisting his editorial changes on 
papers which I wrote because I did not want to be a mere 
mimic. One of Magoun's stylistic quirks was to begin 
sentences with the preposition for ("For we now understand 
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· . "). He slaved over manuscripts, eliminating 
redundancies. 
To me, Magoun's 1949 paper with Moruzzi was the 
cornerstone of his monumental contributions toward an 
understanding of the behavioral significance of the 
reticular formation. The idea of an extraleminscal sensory 
system which ran through the reticular formation already was 
there from some of Magoun's own previous observations, those 
of Ransom, and more obscurely in the seminal observations of 
Bremer. However, these were patches in the crazy quilt 
until the paper of Moruzzi and Magoun made everything 
comprehensible. Moruzzi apparently had added a technologic 
component (electrophysiology) to Magoun's classic anatomic 
techniques which made it possible to give substance to the 
concept. I was led to believe, or perhaps I merely assumed, 
that in turn this technology had been imparted to Moruzzi by 
Lord Adrian (England). 
Such a historical backdrop, if it is accurate (and I 
believe it to be), helps explain the idolatry for Magoun 
exhibited by those whose reflections later appeared in the 
history of the first quarter century of the UCLA Brain 
Institute. Like me, all of Magoun's co-workers appeared to 
see him as the locomotive of the train to which they were 
permitted and encouraged to attach and contribute great or 
small things in their own right. The article by Moruzzi and 
Magoun contained the synthesis of Magoun1s life's work and 
in my opinion is one of the truly great articles in the 
history of science. I have been puzzled through the years 
why Magoun did not become a Nobel Laureate when other 
related work (that of Hess, for example, in the same field) 
resulted in this distinction. 
In my autobiography (Chapter 3), I described the events 
in the summer of 1949 which permanently changed my life. 
With his principal collaborators gone or inactive, Magoun 
devoted much time to my training, beginning by showing me 
the neuropathologic techniques of brain preparation which he 
used to study the tracks left by stimulating, recording, and 
electrocoagulation needles which were inserted into the 
brain stem. 
The map for anatomic localization was an atlas of the 
cat brain prepared by a spaniard (or possibly South 
American) named Jimenez-Castellanos who had recently left 
Northwestern. The readings and drawings of the ne~dle 
tracks were done in a tiny room which contained a microscope 
with an overhead projector, the images from which were 
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traced on fine paper. During the summer, a young staff 
neurosurgeon named Charlie Taylor joined us on a sabbatical 
from the University of Toronto. 
My original assignment was to systemically apply single 
shock and high frequency stimulation to areas in the 
thalamus and reticular formation, and to record the 
electrical changes in various cortical and subcortical 
areas. The objective was to determine how the impulses from 
the reticular formation reached their cortical destination. 
The conclusion was that there were both transthalamic and 
capsular pathways. 
The basis for the second paper was Magoun's suspicion 
that the transthalamic route was the same as the "diffuse 
thalamic projection system" discovered several years earlier 
by Dempsey and Morison of Harvard. However, the Boston 
experiments had been performed under barbiturate anesthesia 
(Dial) which depressed the reticular formation fairly 
specifically and prevented delineation of the true character 
of this system or how it might modulate cortical or 
subcortical electrical activity. In both the first and 
second study, we used Bremer's encephale isole preparation. 
However, for the diffuse thalamic project we used repetitive 
slow stimulation to show a series of projections, primarily 
to the association cortices, from the medially located 
diffuse thalamic projection nuclei. 
These experiments involved stimUlation of subcortical 
areas with recording at a more cephalic level. They did not 
address what was feeding the reticular formation from below. 
One afternoon in June or July, 1949, before I was 
disciplined enough to refrain from deviating from protocol, 
a much more important observation surfaced. For no good 
reason, I switched the leads around so that the stimulating 
electrode was used for recording. 
I was startled to see that substantial electrical 
activity could be picked up in the reticular formation and 
that this was significantly altered by noise such as that 
caused by a door slamming, a toy cricket, or an animal cry. 
I can remember bursting into Magoun's office, and how 
excited he was to hear the news. He came inside the wire 
cage with me where we spent a long time looking for 
artifacts. At first we searched for movement of the cat's 
ears, but the findings were unchanged by giving a large dose 
of a curare-like drug. 
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In Magoun's earlier paper with Moruzzi, ~onclusion 9 in 
the summary was "The possibility that the cortical arousal 
reaction to natural stimuli is mediated by collaterals of 
afferent pathways to the brain stem reticular formation, and 
thence through the ascending reticular activating system, 
rather than by intracortical spread following the arrival of 
afferent impulses at the sensory receiving areas of the 
cortex, is under investigation". The same hypothesis, and 
circumstantial support for it, was an important part of the 
two 1949 Lindsley papers. Now Magoun knew that these 
collateral pathways which had been very difficult to 
demonstrate with classical anatomic techniques, were 
susceptible to systematic electrophysiologic exploration. 
The magnitude of the opportunity was stunning. Shortly 
afterward, I went to the Dean's office and gave notice that 
I was dropping out of medical school for at least one year. 
From this time until his departure for California in the 
late spring of 1950, Magoun and I worked all day, almost 
every day of the week, doing the experiments which we 
published together in the Journal of Neurophysiology in 
1951. At noon, we invariably walked the several blocks to 
the Allerton Cafeteria on Michigan Avenue where we had lunch 
as I described in Chapter 3 of the autobiography. Because 
we were together so much, and because there was a physical 
resemblance, the preposterous rumor found its way back to me 
that I was Magoun's illegitimate son from some earlier 
youthful venture. 
Quitting medical school was not easy to explain to 
anyone at Northwestern, or for that matter to my family in 
Iowa. Although I had discontinued all financial support 
from my father (see Chapter 3), I honored and respected him 
above all others. Magoun realized the quandary and wrote a 
touching letter to my father which he kept at his bedside 
for many years after he became invalided. The letter was 
lost when he died in 1976, but I remember it well and would 
blush to quote it. Magoun was determined that I should stay 
in research and explained why in his letter to my father. 
Eventually, I was half ashamed to follow a different 
pathway. 
It may be that I came to know Magoun better than almost 
anyone else. I learned from him firsthand the price of 
having a creative vision. He lived in a flat on the south 
side of Chicago where he tried to juggle the needs of his 
family with the pressures caused by his discoveries and 
work. His wife, Jean, already was chronically ill. A 
beautiful teenage daughter (and I do not use the adjective 
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lightly) married someone of whom he disapproved. He yearned 
for a more tranquil life. Whether he found this peace in 
california, you would know better than I. 
At scientific meetings, Magoun radiated charm and 
confidence, but behind the facade I thought that he was shy. 
During his Chicago period, he was the nuclear figure in a 
neuroscience brain trust which was interinstitutional. 
Weiner (the father of cybernetics) often came there from 
Boston. Others included Warren McCulloch, Perciful Bailey, 
Ralph Gerard, and several people from a downstate 
psychiatric institute in Mantino, Illinois. I am sure that 
they were all brilliant, but one thing I noticed in their 
meetings was that they fell silent when Magoun spoke. 
I am sure that you will not want to include the 
following anecdote, but I will relate it anyway because it 
was the most devastating putdown I have ever witnessed in my 
life. One day, Magoun took me to a neurophysiology meeting 
at the University of Chicago, where Ralph Gerard worked. 
Gerard could scarcely be missed in a crowd because he was 
extremely overweight. Apparently believing that Magoun was 
sensitive about being bald, Gerard rushed over and greeted 
him by saying "Tid, your head has gotten as bald as my 
wife's ass". I remember how Magoun flushed, and I knew that 
he was genuinely offended. Gravely he examined his own 
scalp, as if comparing it to something, and then replied, 
"By God, Ralph/ I think you're right". I never saw Gerard 
again, but I doubt if he forgot the riposte and the roar of 
laughter which followed. I still smile. 
Magoun left Northwestern in Mayor early June, 1950. 
We were unable to finish our manuscripts because all of the 
experiments had not been completed. Throughout the summer, 
I worked on these and eventually sent drafts to Magoun in 
California which he revised them and added the often 
reproduced Figure 8 in the afferent collateral paper. Some 
time in the autumn, after I had returned to my junior year 
of medical school, Magoun wrote that he could provide a 
traveling fellowship for me if I wanted to come to UCLA the 
following May (1951). 
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My papers from the Northwestern period, and the later 
ones at UCLA were as follows: 
1. Starzl TE and Carpenter W: Diffuse thalamic 
projections to the telencephalon. Anat Rec (Abstract) 
106:250, 1950. 
2. Starzl TE and Magoun HW: Organization of the 
diffuse thalamic projection system. J Neurophysiol 14:133-
146, 1951. 
3. starzl TE, Taylor CW and Magoun HW: Ascending 
conduction in reticular activating system, with special 
reference to the diencephalon. J Neurophysiol 14:461-477, 
1951. 
*4. Starzl TE, Taylor CW and Magoun HW: Collateral 
afferent excitation of reticular formation of brain stem. J 
Neurophysiol 14:479-496, 1951. 
5. Starzl TE and Whitlock DG: Diffuse thalamic 
projection system in monkey. J Neurophysiol 15:449-468, 
1952. 
6. Starzl TE, Neimer WT, Dell M and Forgrave PR: 
Cortical and subcortical electrical activity in experimental 
seizures induced by metrazol. J Neuropathol Exp Neurol 
12:262-276, 1953. 
*Of these, the one on collateral afferent 
excitation was the most important, or so I thought 
then and still believe. The introduction (next 
page) describes the ambiguous situation as we 
encountered it. The summary (the page after that) 
was so brief because the findings and implications 
were so clean. I carried the article in my heart 
for the rest of my life, never believing that I 
could do so well again. 
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COLL;\TERAL AFFERENT· EXCITATION OF 
RETICULAR FORIvIATION OF BRAIN STEM 
T. E. STARZL. C. W. TAYLOR" A.ND H. W. MAGOUNt 
Deparrmenc of Anatomy, Northwestern UnWerBiry Medi.co1 School.t Chicago, lllinoiJI 
(Received for publication December 26, 1950) 
THE demonstrable capacity of afferent stimulation to arouse a sleeping sub-
ject, and the obvious benefits of reducing sensory inflow in predisposing to 
sleep, are in seeming disharmony with recently discovered influences for 
wakefulness exerted by the central reticular core of the brain stem. Direct . 
stimulation of this part of the neuraxis reproduces the electrical pattern of 
wakefulness in the cerebral cortex (14) while at the same time it facilitates 
lower motor activity (16), and so arouses the nervous system generally (9). 
The ascending course of this reticular activating system is diatinct from 
that of afferent pathways in the brain stem (19) and selective destruction 
of its cephalic portion is followed by the EEG synchrony and behavioral 
somnolence, hitherto attributed to deafferentation of the cerebrum (7, 8). 
Such consequences do not follow selectfv8'interruption of ascending somatic 
and auditory paths in the midbrain and after this latter injury both somatic 
and auditory stimuli are still capable of awakening the sleeping animal and 
activating its ERG (7, 8). 
It seemed likely that the apparent conflict might be resolved if evidence 
were forthcoming that collaterals from afferent paths turned into the re-
ticular activating system in the brain stem and exerted their admittedly 
important arousing and awakening influences, indirectly, by modifying its 
activity. 
The present study has explored this possibility by probing the brain 
stem for alterations in electrical activity evoked by somatic and auditory 
stimuli. The findings establish the existence of collaterals from these sensory 
symema to the brain stem reticular formation, the rich wealth of which has 
never previously been suspected. though indications for it have been af-
forded by earlier anatomical investigation (2, 11, 13) and by study of the· 
atypical route of conduction of the 'secondary response' to sciatic stimula-
tion (5). 
Though the results are presented here only with reference to the problem 
:mder discusB:ion. it is felt that implications of these findings may be broad 
indeed, for they appear to enlarge outlooks in afferent conduction far beyond 
those which have been envisioned within the circ:umacribed limits imposed 
by classical sensory paths. • 
.. Department of keuros~ryI University of Toronto. Medical ae-rch Fellow, 
Natlonal Research Council of Canada. 
t School of Medicine. Univenn1:v of California a1: Las>A.nsI;el.ee. . 
; Aided by a grant from the Commonwealth Fund. . 
Reorinted f l'0IlIi 
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ASCENDING RETICULAR ACTIVATING 
SYSTEM IN BRAIN STEM 
Frc. 8. Outline of brain of cat. showing distribution of afferent collaterals to 
ascending reticular activating system in brain stem. 
SU1dMA.RY 
The distribution of afferent collaterals to the reticular formation of the 
brain stem has been investigated in the cat by probing for potential changes 
evoked by somatic and auditory stimulation. 
In the case of each modality, a rich supply of collateral connections to 
the midbrain tegmentum. sub- and hypothalamus and ventromedial thala-
mus was encountered. These findings offer an explanation for a number of 
the generalized consequences of afferent stimulation which have been diffi-
cult to understand in terms of conduction within classical sensory paths. 
Specifically, they indicate that the arousing and awakening influences of 
, sensory stimulation may be exerted indirectly, and at a subcortical leveL by 
collateral excitation of the reticular activating system in the brain stem. 
Reprinted tram-
J. N europh"jSlOJ .• 195114: 479-496 
..L.J.. 
Throughout the entire period from 1948 until my 
departure for California, I had worked as an industrial 
surgeon at night, as I described in my autobiography. I 
quit this job, picked up my two sisters in Iowa, and drove 
to the Long Beach VA Hospital which had the only available 
laboratory facility. There I met Jack French and Mr. 
Edwards (the Hospital Director) and the other people who 
were laying the groundwork for the UCLA Brain Institute. 
There was no activity going on, but provisions had been made 
for monkeys and for operating facilities. 
Dave Whitlock, a graduate stUdent who had just 
completed his Ph.D. requirements, arrived from the 
University of Oregon with his wife, Peggy. I lived on the 
VA Hospital base. The Whitlock's had a small house in Long 
Beach where I spent many evenings. I tracked Dave from 
place to place after this, and eventually was able to 
nominate him for the Chairmanship of Anatomy at the 
University of Colorado where I was working myself. He 
accepted the job and we were reunited almost 20 years later. 
My primary objective in Long Beach was to map the 
projections of the diffuse thalamic projection system in the 
primate, because the monkey had much more extensive cortical 
association areas than the cat. The results were largely 
confirmatory of those in the cat, although there was a much 
stronger localization of the medial thalamic nuclei 
projections to specific cortical association areas as well 
as an overall dominance in the frontal lobes and cingulate 
gyrus. 
In a second study in cats, we tried to determine if 
metrazol seizures were initiated in the subcortical areas 
and radiated to the cortex. This was an attempt to verify a 
hypothesis by Jasper about the deep initiation of seizures, 
but to our disappointment these appeared to start in the 
cortex and could be invoked best by stimUlation of the 
classical sensory pathways. The seizures then spread across 
the cortex and antidromically to the diencephalon. 
I cannot remember a more happy time than the summer of 
1951. The place where I lived on the VA Hospital base was 
Spartan, but it was clear that French and Magoun had created 
an idyllic place to work. Play was not totally ignored. 
There was a small golf course on the station, and just 
across Highway One were numerous alluring places to go late 
at night. The Pike (an amusement park, now gone) was at the 
height of its popularity. Twenty miles to the south was 
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Christian1s Hut where we had an overly hedonistic farewell 
party the weekend before I left. 
Magoun was concerned at one time that I was neglecting 
my social life. It would have relieved him (or possibly the 
opposite) if I had shared all secrets. I did not know 
anyone of my own age when I arrived, and after a few days I 
drove up the Pasadena Freeway and on to the Los Angeles 
County Hospital where I conducted a survey of the first 8 or 
10 interns and residents whom I encountered. I asked them 
"Who is the most attractive student nurse in the hospital?". 
All but 2 or 3 identified a young lady named Marilyn Conner. 
I tracked her to the ward where she was working the night 
shift, explained exactly how I had identified her, and asked 
her if she would join me for a snack after work (which she 
did), Unfortunately, she was in love with a medical student 
at the University of California, San Francisco, and soon was 
borrowing money from me to take the train on the weekends to 
see him. 
During my last week in Los Angeles, she learned that 
her San Francisco friend had become engaged to someone else, 
emancipating her from further obligations and leaving her 
free as she saw it to join me in Chicago. Somehow, it did 
not fit my preconceived romantic scenario, and I never saw 
her again. Jack French met Marilyn at about this time, 
probably at the Christian's Hut party. He was unattached 
and I believe that they saw each other after this. 
Apparently, Jack was very popular, and was just coming off 
of a romance with Ava Gardner when I arrived. 
About 35 years later, I was saddened to receive a 
letter from Marilyn who now lives some place in Oregon. She 
had developed renal failure, and was inquiring about the 
best place to have a kidney transplantation. In her long 
letter, she told me of her numerous adventures in life. Now 
she had grown old and sick. Even the most beautiful flowers 
bloom and wither like all the rest. 
During the end of my stay in Los Angeles, Magoun 
approached me about taking a fellowship at the Karolinska 
Institute with Ragnar Granit, instead of returning to my 
senior year. I knew by this time that I wanted to practice 
surgery, primarily because the complex technical procedures 
required to do the experiments with Magoun had seemed so 
easy to me. Incidentally, Magoun himself was a master 
surgeon., more skillful in the performance of fine work, in 
my opinion, than any surgeon whom I have ever watched in the 
clinical operating room. 
Until he left Northwestern, Hagoun did all of his own 
experiments, and was an active participant in the smallest 
detail of the benchwork. He had an obsession for accuracy 
which caused some people to·believe he had a fiery temper. 
His pursuit of an idea was so passionate that I believe he 
suffered intensely at the time of his highest creativity. I 
realized from talking to him that he did not intend to 
return to this way of life, and that probably I would be the 
last person he would work with shoulder to shoulder. He was 
only 43 years old. As it turned out, he had many other 
useful ways to serve out the remaining 40 years. 
On the way back from Los Angeles, I drove to Salt Lake 
City, and gave a paper at the autumn meeting of the American 
Physiology Society. It was a sad departure, because I 
realized that I might never see Magoun again. In fact, I 
met him only once when he came to a neurophysiology 
conference at Northwestern in the late 1950's. He was 
grayer then, but otherwise much the same. Now at the peak 
of his prestige, he was surrounded by admirers who were 
speaking a language which I no longer understood. 
I do not remember Joe Bogen. If you would like to know 
more, please write again. What I did in the rest of my life 
is in the book, and in the enclosed Chapter which I 
contributed to Paul Terasaki's recent history of 
transplantation (UCLA Press). It was all an anticlimax. At 
the back of the chapter is an abbreviated C.V. 
In my book (pages 40-41) I tried to explain my debt to 
Magoun, in fewer words than in this letter, and possibly 
better. I was planning to send the book to him, but when I 
asked Don Lindsley's son about him last May, I learned that 
he had died~s before. 
Sincerely/' GtP,\' 
( -K~ ~K 
,/ 
Thomas E. Starzl, M.D., Ph.D. 
Professor of Surgery 
TESjps 
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S&l..ffk!. ..-r.tt ~ a"tk4dt :c -F1 j. C m~tt+gI>: At:~¥D;~IKKK 
UNIVERSITY OF CAUFORNIA: 
-1.05 ANGEUS ~+ CAUFOJUHA ~eoartment of .\natoJ1't,1 
School of Medicine 
December O~P 1951 
Dr. Alfred Blalock 
J oms -Hopk:ins Eospita.l 
Baltimore II~lKKK:arKrlaKnd 
Dear' Doctor Elalock: 
:Cam ~1riting you in cozme.ction with t!:oe application of ioJr. Tho.U5 E. 
Starz1 .. for an inte:n:::hip at Johns tlopki.::ls nospita1 in the year 1952 to 1953. 
Mr;Starzl will. e~~cd"KKlate 1.:1 medicine from N'orthweste=n Universit7 School.of 
Medicine inKg~eI 1952, and ~KlgK rscaiva his Ph.D. at tr~ sam~ t~£K 1_ 
have been c1o~ely acquainted with !-1~K sta~l during three of -his years· at, 
Northwestern and again last SUI:l:'Ilel" at UCL.<t. . 
Hr. Starzl ts a :rBeK;IKIaopea:-in~! c~DanD gd:., oermvat., 9 79\4R!! . man 
who is one of tte most Qutstanrl-i..'"1G i'!edica1 s~-:Kde!1ts '''I'ith l.f.lom it h<Ks·~"Der 
been mv pleasure to beaC:luainted. ~ ha·s c:msta.'"1tl ". stooei-_ a-: or' near the· 
~ top 01:- his- class, a:1.·i he i.::. a pro,digiou5 worKe.;r rm-o' has far" exce'edsd' the 
ordinarv accomolisi:Jr.;"3I!-£s of =a·die.:!;:!. et::xi:ents...... -~Kw .. • 
Mr. Sta:-z1 !1a s: soent eDPKc~ ~i!! SUInJne,rs and a 'rear 'c:e:tween the 
s~homore and junior years' of r:is. meciica:lp'!"CIg,!"a:::L in kKs~PKrch-work .. ir~ tIle 
experimentalneu::"':llogy- laKbc~otv "..lIlC:e·r m:ysDr!le-nsian~KiK have· !'lever kno~m 
a ;Z9Ue"1g man !Wa s!:;.Qwed such ca:oatility i."J.. ra=idJ.:r :-as?j~dKrKhe~:iclyg!"D!llnd 
of" a nroblaJ"l1., ':;'is i!:!3"'; -', i.."1 c:l!'lceiv-i-!lg .!'lew. ±d·II~ s to:r e:-KK~lCFrPK:ion is 
~tandingI ;md he pos"'es"'"'s a rema!"K;,:!l::!S at· ~:u_b:i esi~ tiD!~ ~xperi­
mental a"Ol:roaches to tast such ~ossiKbil:KtiesK .Ln e3.ch research team ,v:.tl::! 
w • - :l,l'jled lea:lers.nin and carried. tre '1\ai 
bu~-en of tl":e wouc. His r<:!~:!aKrci1 accomplis.':.r.Ie!lt for a ;rounp; Il12."l ot ~is 
age is, in~ opinion, 'l.."li=!'le. ;:e is the ch,.ie! a:'l't.:.cr 9: thre- p11blished 
pape:-s a."ld one additional pCl~Dpr no .. accepted for pDKlblic~tionK THO ?tr.er 
~ajor projects to .mich h:; contrio::ted heaVily a~ noW' c::i!'le; p:-epared for 
public <I 'C ion. L'"l ali of th:"5 e::rne!"i.':ten .. ;l a.':!..":Ial work: ·M~K Sta::-'z:l has been 
a1a~ t~ tte L'"'!t'l:"caticns of the :::r - .' r-' .... .,1 -"ea:'cL'"1e. 
_'"1 !lis pre ecnt clerK:s.hip at. Passavant eu~ ir.al .L.l Chicat,;o, he ~Dqri:DD:?:;: of 
the clinical. i:westig~DCive :!.ctivit7 which he··is 1ladertaki::~ i.::. add:':ticn 
to the !"P.g1.llar pr:::lgram. 
r-!~K pta~zl is L'1tent :m ~nteT"iKD1g surger:.r as i1 cE.!'!'!er, :.r.:i I am 
confi:::i'=!1t that ~9 rill bec~tK1e one 0;" tr.e 01ltsta:1d.:':;g fi.f".l:'es :L., t::'is f~eld 
in the ':uture. :wol1l1 rate !Jim as acsolutely the ton mnn ttat. I have 
i~Im:li:nt!e--K4 riu "",;,,&.: Dln~D" +,·r.mty ye<'_rs of association ~;ith ned:'cal stuCepts· 
: 1""!coITCend him to t~e att-:r.tion 0':: your ::'!'lternship commit~€:ta in ~he V9!,",.! 
highest poss~c1a ter.ns. 
,. ... ..f.t.l'&.J _"'t 
Ver'.r ~inKr:sK:-el~q :rour:: J 
t+. L,v. DvnK~/~ 
H. !.f. 71a.go un 
Professor and Cha:D~an 
~~n~rt~en~ of AnaKtnm~ 
Medicine/ Current Affairs 
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